Nano-X Imaging price target raised to $12 from $11 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Nano-X Imaging (NNOX) to $12 from $11 and keeps an Overweight rating on the shares. After the company received FDA 510(k) expanded indication for full-body scans, Cantor says the company discussed that roughly 50% of existing leads were waiting on the expanded indication for chest scans, which should also drive drive adoption in the hospital setting given the expanded indication, the analyst tells investors in a research note. The firm raised its 2025 and 2026 revenue estimates to $46.3M and $147.2M from $43.1M and $140.7M.